[go: up one dir, main page]

UA114405C2 - Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу - Google Patents

Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу

Info

Publication number
UA114405C2
UA114405C2 UAA201402017A UAA201402017A UA114405C2 UA 114405 C2 UA114405 C2 UA 114405C2 UA A201402017 A UAA201402017 A UA A201402017A UA A201402017 A UAA201402017 A UA A201402017A UA 114405 C2 UA114405 C2 UA 114405C2
Authority
UA
Ukraine
Prior art keywords
compounds
hex
schizophrenia
general formula
phenyl
Prior art date
Application number
UAA201402017A
Other languages
English (en)
Inventor
Ріккардо Джованніні
Барбара Бертані
Марко Феррара
Іен Лінгард
Рокко Маццаферро
Хольгер Розенброк
Original Assignee
Бьорінгер Інгельхайм Інтернаціональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорінгер Інгельхайм Інтернаціональ Гмбх filed Critical Бьорінгер Інгельхайм Інтернаціональ Гмбх
Publication of UA114405C2 publication Critical patent/UA114405C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

У заявці описані заміщені феніл-3-азабіцикло[3.1.0]гекс-3-илметанони загальної формули (І) EMBED ISISServer , (I) в якій R1, R2, R3, R4, R5 i R6 є такими, як описано в даному винаході, і їх солі, краще їх фармацевтично прийнятні солі. У заявці також описані отримання зазначених сполук, фармацевтичні композиції, що містять сполуки загальної формули (І), і застосування зазначених сполук для лікування різних патологічних станів, таких як патологічні стани, пов'язані з позитивними і негативними симптомами шизофренії, а також порушень пізнавальної здатності, пов'язаних із шизофренією, хворобою Альцгеймера і іншими неврологічними і психічними порушеннями. Сполуки, запропоновані в даному винаході, мають здатність інгібувати переносник-1 гліцину (GlyT1).
UAA201402017A 2011-08-03 2012-08-02 Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу UA114405C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176468 2011-08-03
PCT/EP2012/065140 WO2013017657A1 (en) 2011-08-03 2012-08-02 Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Publications (1)

Publication Number Publication Date
UA114405C2 true UA114405C2 (uk) 2017-06-12

Family

ID=46598566

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201402017A UA114405C2 (uk) 2011-08-03 2012-08-02 Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу

Country Status (37)

Country Link
US (1) US9012489B2 (uk)
EP (1) EP2739615B1 (uk)
JP (1) JP5850589B2 (uk)
KR (1) KR101944686B1 (uk)
CN (2) CN105837562B (uk)
AP (1) AP2014007399A0 (uk)
AR (1) AR087436A1 (uk)
AU (1) AU2012292036C1 (uk)
BR (1) BR112014001642B1 (uk)
CA (1) CA2843805C (uk)
CL (1) CL2014000246A1 (uk)
CO (1) CO6870037A2 (uk)
CY (1) CY1119326T1 (uk)
DK (1) DK2739615T3 (uk)
EA (1) EA024933B1 (uk)
EC (1) ECSP14013221A (uk)
ES (1) ES2623006T3 (uk)
GE (1) GEP20166483B (uk)
HR (1) HRP20170695T1 (uk)
HU (1) HUE033134T2 (uk)
IL (1) IL229962A (uk)
LT (1) LT2739615T (uk)
MA (1) MA35286B1 (uk)
ME (1) ME02672B (uk)
MX (1) MX347828B (uk)
MY (1) MY167396A (uk)
PE (1) PE20141352A1 (uk)
PH (1) PH12014500276A1 (uk)
PL (1) PL2739615T3 (uk)
PT (1) PT2739615T (uk)
RS (1) RS55927B1 (uk)
SI (1) SI2739615T1 (uk)
TN (1) TN2014000044A1 (uk)
TW (1) TWI543974B (uk)
UA (1) UA114405C2 (uk)
UY (1) UY34239A (uk)
WO (1) WO2013017657A1 (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027983B1 (pt) 2014-06-06 2021-11-03 Basf Se Uso dos compostos, composição agroquímica e método para o combate dos fungos fitopatogênicos
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
EP3373735A1 (en) 2015-11-13 2018-09-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017085100A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
BR112018069897B1 (pt) 2016-04-11 2023-01-17 Basf Se Composto de fórmula i, composição agroquímica, processo para a preparação de compostos de fórmula i, uso não terapêutico de compostos e método para o combate de fungos fitopatogênicos nocivos
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
AU2020266566B2 (en) * 2019-05-01 2025-11-06 Boehringer Ingelheim International Gmbh Solid forms of a GlyT1 inhibitor
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US12059408B2 (en) * 2020-08-13 2024-08-13 Boehringer Ingelheim International Gmbh Treatment of cognitive impairment associated with schizophrenia
WO2022078927A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking
EP4436564A4 (en) * 2021-11-24 2025-10-22 Maplight Therapeutics Inc METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
WO2023237103A1 (zh) * 2022-06-10 2023-12-14 成都百裕制药股份有限公司 吡咯烷衍生物、药物组合物及其在医药上的应用
AU2023328948A1 (en) 2022-08-24 2025-01-16 Boehringer Ingelheim International Gmbh A scalable process for the preparation of a glyt-1 inhibitor
WO2024243600A2 (en) * 2023-05-25 2024-11-28 Maplight Therapeutics, Inc. Compositions for treating neurological disorders
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521788A1 (en) * 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ES2634841T3 (es) 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
DE102004035280A1 (de) 2004-07-21 2006-03-16 Robert Bosch Gmbh Kraftstoffinjektor mit direkter mehrstufiger Einspritzventilgliedansteuerung
EP1836178A1 (en) * 2005-01-06 2007-09-26 F. Hoffmann-Roche AG Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
BRPI0519794A2 (pt) * 2005-01-07 2009-03-17 Hoffmann La Roche derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
DK1848694T3 (da) * 2005-02-07 2010-01-25 Hoffmann La Roche Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
ES2406085T3 (es) * 2006-06-22 2013-06-05 F. Hoffmann-La Roche Ag Derivados de fenil-metanona sustituida y su empleo como inhibidores de receptores de GlyT1 y GlyT2
JP5179486B2 (ja) 2006-06-28 2013-04-10 アムジエン・インコーポレーテツド グリシン輸送体−1阻害剤
CL2007003827A1 (es) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
RU2011124709A (ru) * 2008-12-29 2013-02-10 Вандербилт Юниверсити ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2517701C2 (ru) 2009-01-27 2014-05-27 Ф. Хоффманн-Ля Рош Аг Ароиламино- и гетероароиламино-замещенные пиперидины в качестве ингибиторов glyt-1

Also Published As

Publication number Publication date
AU2012292036C1 (en) 2017-03-23
ME02672B (me) 2017-06-20
JP2014524414A (ja) 2014-09-22
HK1193100A1 (zh) 2014-09-12
GEP20166483B (en) 2016-05-25
CN103797005A (zh) 2014-05-14
CL2014000246A1 (es) 2014-08-08
AU2012292036B2 (en) 2016-10-06
PT2739615T (pt) 2017-06-09
NZ619258A (en) 2015-12-24
CA2843805C (en) 2021-03-23
TN2014000044A1 (en) 2015-07-01
AP2014007399A0 (en) 2014-01-31
JP5850589B2 (ja) 2016-02-03
HUE033134T2 (en) 2017-11-28
DK2739615T3 (en) 2017-05-08
MX2014001252A (es) 2014-05-13
LT2739615T (lt) 2017-04-10
MY167396A (en) 2018-08-16
MA35286B1 (fr) 2014-07-03
CO6870037A2 (es) 2014-02-20
CA2843805A1 (en) 2013-02-07
EP2739615A1 (en) 2014-06-11
US9012489B2 (en) 2015-04-21
EA201400183A1 (ru) 2014-06-30
TW201321364A (zh) 2013-06-01
EP2739615B1 (en) 2017-03-15
SI2739615T1 (sl) 2017-07-31
AU2012292036A1 (en) 2014-01-16
CN105837562A (zh) 2016-08-10
ES2623006T3 (es) 2017-07-10
MX347828B (es) 2017-05-15
CY1119326T1 (el) 2018-02-14
BR112014001642A2 (pt) 2017-02-14
PE20141352A1 (es) 2014-10-12
HRP20170695T1 (hr) 2017-07-28
TWI543974B (zh) 2016-08-01
PL2739615T3 (pl) 2017-08-31
AR087436A1 (es) 2014-03-26
CN105837562B (zh) 2020-01-17
RS55927B1 (sr) 2017-09-29
WO2013017657A1 (en) 2013-02-07
US20130197011A1 (en) 2013-08-01
IL229962A (en) 2016-09-29
BR112014001642B1 (pt) 2022-03-22
KR101944686B1 (ko) 2019-02-01
ECSP14013221A (es) 2014-03-31
PH12014500276A1 (en) 2017-02-01
EA024933B1 (ru) 2016-11-30
KR20140051922A (ko) 2014-05-02
UY34239A (es) 2013-02-28
CN103797005B (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
MY158974A (en) Prodrugs comprising an exendin linker conjugate
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
MX347706B (es) Derivados de triazol y su uso para trastornos neurologicos.
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
TN2012000011A1 (en) Prodrugs comprising an insulin linker conjugate
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
SI2875011T1 (en) 5-HT3 receptor antagonists
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX355142B (es) Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor).
WO2011159124A3 (ko) Interleukin-6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2010048452A3 (en) Polycyclic compounds and methods related thereto
IN2015DN01900A (uk)
MX2013005965A (es) Nuevos compuestos de triazol iii.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
IN2012DN02005A (uk)
EA201001095A1 (ru) Соединение (r)-n*6*-этил-6,7-дигидро-5н-индено[5,6-d]тиазол-2,6-диамин и его применение в качестве антипсихотического средства